PTGX Quote, Financials, Valuation and Earnings

Bristol Myers Squibb Co. has a net margin of -834.87% compared to Protagonist Therapeutics, Inc.'s net margin of 17.96%. Protagonist Therapeutics, Inc.'s return on equity of 7.15% beat Bristol Myers Squibb Co.'s return on equity of 34.7%.

Protagonist Therapeutics, Inc. has a consensus price target of $90.69, signalling upside risk potential of 5.37%. On the other hand Bristol Myers Squibb Co. has an analysts' consensus of $53.41 which suggests that it could grow by 2.81%. Given that Protagonist Therapeutics, Inc. has higher upside potential than Bristol Myers Squibb Co., analysts believe Protagonist Therapeutics, Inc. is more attractive than Bristol Myers Squibb Co..

Protagonist Therapeutics, Inc. has a beta of 2.192, which suggesting that the stock is 119.221% more volatile than S&P 500. In comparison Bristol Myers Squibb Co. has a beta of 0.296, suggesting its less volatile than the S&P 500 by 70.363%.

Protagonist Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bristol Myers Squibb Co. offers a yield of 4.77% to investors and pays a quarterly dividend of $0.62 per share. Protagonist Therapeutics, Inc. pays -- of its earnings as a dividend. Bristol Myers Squibb Co. pays out 54.44% of its earnings as a dividend. Bristol Myers Squibb Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Protagonist Therapeutics, Inc. quarterly revenues are $4.7M, which are smaller than Bristol Myers Squibb Co. quarterly revenues of $12.2B. Protagonist Therapeutics, Inc.'s net income of -$39.3M is lower than Bristol Myers Squibb Co.'s net income of $2.2B. Notably, Protagonist Therapeutics, Inc.'s price-to-earnings ratio is 135.91x while Bristol Myers Squibb Co.'s PE ratio is 17.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protagonist Therapeutics, Inc. is 26.40x versus 2.20x for Bristol Myers Squibb Co.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of -834.87% compared to Protagonist Therapeutics, Inc.'s net margin of 21.47%. Protagonist Therapeutics, Inc.'s return on equity of 7.15% beat Johnson & Johnson's return on equity of 33.27%.

Protagonist Therapeutics, Inc. has a consensus price target of $90.69, signalling upside risk potential of 5.37%. On the other hand Johnson & Johnson has an analysts' consensus of $202.54 which suggests that it could fall by -1.36%. Given that Protagonist Therapeutics, Inc. has higher upside potential than Johnson & Johnson, analysts believe Protagonist Therapeutics, Inc. is more attractive than Johnson & Johnson.

Protagonist Therapeutics, Inc. has a beta of 2.192, which suggesting that the stock is 119.221% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.296%.

Protagonist Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.5% to investors and pays a quarterly dividend of $1.30 per share. Protagonist Therapeutics, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Protagonist Therapeutics, Inc. quarterly revenues are $4.7M, which are smaller than Johnson & Johnson quarterly revenues of $24B. Protagonist Therapeutics, Inc.'s net income of -$39.3M is lower than Johnson & Johnson's net income of $5.2B. Notably, Protagonist Therapeutics, Inc.'s price-to-earnings ratio is 135.91x while Johnson & Johnson's PE ratio is 19.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protagonist Therapeutics, Inc. is 26.40x versus 5.40x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -834.87% compared to Protagonist Therapeutics, Inc.'s net margin of 38.89%. Protagonist Therapeutics, Inc.'s return on equity of 7.15% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

Protagonist Therapeutics, Inc. has a consensus price target of $90.69, signalling upside risk potential of 5.37%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $768.36 which suggests that it could grow by 6.18%. Given that Regeneron Pharmaceuticals, Inc. has higher upside potential than Protagonist Therapeutics, Inc., analysts believe Regeneron Pharmaceuticals, Inc. is more attractive than Protagonist Therapeutics, Inc..

Protagonist Therapeutics, Inc. has a beta of 2.192, which suggesting that the stock is 119.221% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.095%.

Protagonist Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.49% to investors and pays a quarterly dividend of $0.88 per share. Protagonist Therapeutics, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Protagonist Therapeutics, Inc. quarterly revenues are $4.7M, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Protagonist Therapeutics, Inc.'s net income of -$39.3M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Protagonist Therapeutics, Inc.'s price-to-earnings ratio is 135.91x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 17.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protagonist Therapeutics, Inc. is 26.40x versus 5.60x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vanda Pharmaceuticals, Inc. has a net margin of -834.87% compared to Protagonist Therapeutics, Inc.'s net margin of -40.15%. Protagonist Therapeutics, Inc.'s return on equity of 7.15% beat Vanda Pharmaceuticals, Inc.'s return on equity of -16.55%.

Protagonist Therapeutics, Inc. has a consensus price target of $90.69, signalling upside risk potential of 5.37%. On the other hand Vanda Pharmaceuticals, Inc. has an analysts' consensus of $11.75 which suggests that it could grow by 122.96%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than Protagonist Therapeutics, Inc., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than Protagonist Therapeutics, Inc..

Protagonist Therapeutics, Inc. has a beta of 2.192, which suggesting that the stock is 119.221% more volatile than S&P 500. In comparison Vanda Pharmaceuticals, Inc. has a beta of 0.687, suggesting its less volatile than the S&P 500 by 31.308%.

Protagonist Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protagonist Therapeutics, Inc. pays -- of its earnings as a dividend. Vanda Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Protagonist Therapeutics, Inc. quarterly revenues are $4.7M, which are smaller than Vanda Pharmaceuticals, Inc. quarterly revenues of $56.3M. Protagonist Therapeutics, Inc.'s net income of -$39.3M is lower than Vanda Pharmaceuticals, Inc.'s net income of -$22.6M. Notably, Protagonist Therapeutics, Inc.'s price-to-earnings ratio is 135.91x while Vanda Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protagonist Therapeutics, Inc. is 26.40x versus 1.46x for Vanda Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.